329 related articles for article (PubMed ID: 17804706)
1. Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies.
Jarboe JS; Johnson KR; Choi Y; Lonser RR; Park JK
Cancer Res; 2007 Sep; 67(17):7983-6. PubMed ID: 17804706
[TBL] [Abstract][Full Text] [Related]
2. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.
Kahlon KS; Brown C; Cooper LJ; Raubitschek A; Forman SJ; Jensen MC
Cancer Res; 2004 Dec; 64(24):9160-6. PubMed ID: 15604287
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.
Han J; Puri RK
J Neurooncol; 2018 Feb; 136(3):463-474. PubMed ID: 29168083
[TBL] [Abstract][Full Text] [Related]
4. Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study.
Kim K; Gwak HS; Han N; Hong EK; Choi BK; Lee S; Choi S; Park JH; Seok JH; Jeon Y; Cho H; Lee SJ; Lee Y; Nam KT; Song SW
Front Immunol; 2021; 12():715000. PubMed ID: 34819930
[TBL] [Abstract][Full Text] [Related]
5. Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy.
Saikali S; Avril T; Collet B; Hamlat A; Bansard JY; Drenou B; Guegan Y; Quillien V
J Neurooncol; 2007 Jan; 81(2):139-48. PubMed ID: 17004103
[TBL] [Abstract][Full Text] [Related]
6. A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker.
Nguyen V; Conyers JM; Zhu D; Gibo DM; Hantgan RR; Larson SM; Debinski W; Mintz A
Neuro Oncol; 2012 Oct; 14(10):1239-53. PubMed ID: 22952195
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the prognostic value of CD44 in glioblastoma multiforme.
Wei KC; Huang CY; Chen PY; Feng LY; Wu TW; Chen SM; Tsai HC; Lu YJ; Tsang NM; Tseng CK; Pai PC; Shin JW
Anticancer Res; 2010 Jan; 30(1):253-9. PubMed ID: 20150644
[TBL] [Abstract][Full Text] [Related]
8. Targeting glioblastoma multiforme using a novel fusion protein comprising interleukin-13 and staphylococcal enterotoxin B in vitro.
Gholipour Z; Fooladi AAI; Parivar K; Halabian R
Toxicol In Vitro; 2023 Oct; 92():105651. PubMed ID: 37482138
[TBL] [Abstract][Full Text] [Related]
9. T cells redirected to interleukin-13Rα2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1.
Krebs S; Chow KK; Yi Z; Rodriguez-Cruz T; Hegde M; Gerken C; Ahmed N; Gottschalk S
Cytotherapy; 2014 Aug; 16(8):1121-31. PubMed ID: 24841514
[TBL] [Abstract][Full Text] [Related]
10. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.
Brown CE; Badie B; Barish ME; Weng L; Ostberg JR; Chang WC; Naranjo A; Starr R; Wagner J; Wright C; Zhai Y; Bading JR; Ressler JA; Portnow J; D'Apuzzo M; Forman SJ; Jensen MC
Clin Cancer Res; 2015 Sep; 21(18):4062-72. PubMed ID: 26059190
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets.
Hoelzinger DB; Mariani L; Weis J; Woyke T; Berens TJ; McDonough WS; Sloan A; Coons SW; Berens ME
Neoplasia; 2005 Jan; 7(1):7-16. PubMed ID: 15720813
[TBL] [Abstract][Full Text] [Related]
12. Decreasing expression of the interleukin-13 receptor IL-13Ralpha2 in treated recurrent malignant gliomas.
Bozinov O; Kalk JM; Krayenbühl N; Woernle CM; Sure U; Bertalanffy H
Neurol Med Chir (Tokyo); 2010; 50(8):617-21. PubMed ID: 20805641
[TBL] [Abstract][Full Text] [Related]
13. Reoxygenation of hypoxic glioblastoma multiforme cells potentiates the killing effect of an interleukin-13-based cytotoxin.
Liu TF; Cai J; Gibo DM; Debinski W
Clin Cancer Res; 2009 Jan; 15(1):160-8. PubMed ID: 19118043
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of the alpha2 chain of the interleukin-13 receptor in metastatic human prostate cancer ARCaPM cells.
He H; Xu J; Nelson PS; Marshall FF; Chung LW; Zhau HE; He D; Wang R
Prostate; 2010 Jun; 70(9):993-1001. PubMed ID: 20166133
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional changes in U343 MG-a glioblastoma cell line exposed to ionizing radiation.
Bassi C; Mello SS; Cardoso RS; Godoy PD; Fachin AL; Junta CM; Sandrin-Garcia P; Carlotti CG; Falcão RP; Donadi EA; Passos GA; Sakamoto-Hojo ET
Hum Exp Toxicol; 2008 Dec; 27(12):919-29. PubMed ID: 19273547
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of alpha4 chain-containing laminins in human glial tumors identified by gene microarray analysis.
Ljubimova JY; Lakhter AJ; Loksh A; Yong WH; Riedinger MS; Miner JH; Sorokin LM; Ljubimov AV; Black KL
Cancer Res; 2001 Jul; 61(14):5601-10. PubMed ID: 11454714
[TBL] [Abstract][Full Text] [Related]
17. Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells.
Brown CE; Starr R; Aguilar B; Shami AF; Martinez C; D'Apuzzo M; Barish ME; Forman SJ; Jensen MC
Clin Cancer Res; 2012 Apr; 18(8):2199-209. PubMed ID: 22407828
[TBL] [Abstract][Full Text] [Related]
18. In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures.
Joshi BH; Leland P; Asher A; Prayson RA; Varricchio F; Puri RK
Cancer Res; 2001 Nov; 61(22):8058-61. PubMed ID: 11719427
[TBL] [Abstract][Full Text] [Related]
19. Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme.
Kuan CT; Wakiya K; Dowell JM; Herndon JE; Reardon DA; Graner MW; Riggins GJ; Wikstrand CJ; Bigner DD
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1970-82. PubMed ID: 16609006
[TBL] [Abstract][Full Text] [Related]
20. Identification of histological markers for malignant glioma by genome-wide expression analysis: dynein, alpha-PIX and sorcin.
Yokota T; Kouno J; Adachi K; Takahashi H; Teramoto A; Matsumoto K; Sugisaki Y; Onda M; Tsunoda T
Acta Neuropathol; 2006 Jan; 111(1):29-38. PubMed ID: 16320026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
